Abstract
174 - Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
Highlights
Glioblastoma multiforme (GBM) is an aggressive brain tumor associated with invasive behavior, high rate of recurrence, and an average survival of less than 15 months, irrespective of treatment [1,2,3]
Vosaroxin reduced tumor growth and showed enhanced activity with RT; vosaroxin/RT combined was more effective than temozolomide/RT
Vosaroxin demonstrated significant activity in vitro and in vivo in GBM models, and showed additive/synergistic activity when combined with RT in O6methylguanine methyltransferase-negative and -positive cell lines
Summary
Glioblastoma multiforme (GBM) is an aggressive brain tumor associated with invasive behavior, high rate of recurrence, and an average survival of less than 15 months, irrespective of treatment [1,2,3]. GBM tumors consist of a heterogeneous population of tumor cells and contain immune cells that, with tumor vasculature and the extracellular matrix, constitute the tumor microenvironment. Interactions among these different cell types and cytokines may promote tumor development and progression. TAMs from human neoplasms express arginase 1, interleukin (IL)-10, and transforming growth factor beta (TGF-β); these cytokines reduce the antitumor activity of T cells and natural killer cells, and modulate tumor proliferation, infiltration, and angiogenesis [10]. Cells expressing monocyte and M2 markers are found dispersed throughout the tumor parenchyma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
